MetaCap

Pliant Therapeutics Inc. (PLRX)

NASDAQ: PLRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.5951-0.0249 (-4.02%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PLRX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$36.89M
EPS (TTM)
-$1.46
52-week range
0.5719 – 1.67
Day range
0.5719 – 0.6139
Volume / Avg
933.40K / 408.93K
Beta
—

52-week range

$0.5719$1.67

PLRX stock today

On Nov 20, PLRX ended the session at $0.5951, shedding $0.0249 (4.02%), versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 933.40K shares, a sign of unusually heavy trading. At this level, PLRX sits near the bottom of its 52-week range of $0.5719 to $1.67: 64.4% below the high, set on Dec 4, 2025 and 4.1% above the low.

PLRX is down 51.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 61.6%. Pliant Therapeutics has posted a net loss over the last twelve months (EPS of -$1.46), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Pliant Therapeutics

Company profile

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Bernard Jozef Coulie M.B.A., M.D., Ph.D.
Headquarters
South San Francisco, CA
Employees
49
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Pliant Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Pliant Therapeutics reported a net loss of $149.3 million, compared with a loss of $210.3 million a year earlier. Diluted earnings per share came in at -$2.43.

Pliant Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$0$1.58M$9.69M$7.57M
Growth—-100.00%-83.69%+27.91%-81.89%
Net income$-149.34M$-210.30M$-161.34M$-123.32M$-97.26M
EPS (diluted)$-2.43$-3.47$-2.75$-2.94$-2.71

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$2.00+236.08%

  • Strong buy 0
  • Buy 0
  • Hold 3
  • Sell 0
  • Strong sell 1

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.43 vs $-0.37
Surprise
-16.22%

PLRX news

All PLRX news

Pliant Therapeutics peers

Health Care sector
PLRX peer companies
CompanyPrice% ChgMarket capCompare
SDEVStablecoin Development Corporation0.50-10.30%$36.90Mvs PLRX
GRCEGrace Therapeutics Inc.1.71-0.58%$35.97Mvs PLRX
CNTBConnect Biopharma Holdings Limited0.59-6.08%$38.05Mvs PLRX
CUECue Biopharma Inc.4.15-7.78%$34.69Mvs PLRX
DWTXDogwood Therapeutics Inc.1.04-2.36%$39.57Mvs PLRX
VERUVeru Inc.1.94-8.06%$33.08Mvs PLRX
ATNMActinium Pharmaceuticals Inc. (Delaware)1.05-1.87%$33.01Mvs PLRX
TLPHTalphera Inc.0.7852+6.25%$40.80Mvs PLRX

Indexes, lists and sector

Pliant Therapeutics stock FAQ

What is Pliant Therapeutics's stock price today?

PLRX last traded at $0.5951 as of Nov 20, 4:00 PM EST, down 4.02% on the day. Prices are delayed at least 15 minutes.

Who is Pliant Therapeutics's CEO?

Dr. Bernard Jozef Coulie M.B.A., M.D., Ph.D. is the chief executive officer of Pliant Therapeutics Inc., which has about 49 employees.

What is the PLRX 52-week high?

The 52-week high for PLRX is $1.67 and the 52-week low is $0.5719. The stock is currently 64.4% below its high.

Compare PLRX